Tempus Announced the National Launch of the FDA-Approved xT CDx Test
On January 15, 2025, Tempus AI, Inc., a technology company driving the use of AI to advance precision medicine and improve patient care, announced the nationwide launch of its FDA-approved, NGS-based in vitro diagnostic device, xT CDx. The diagnostic test is available to clinicians nationwide. This FDA-approved test provides comprehensive insights and features one of the largest reported gene panels in the industry.
xT CDx is a next-generation sequencing (NGS) test that analyzes 648 genes for solid tumor profiling, including microsatellite instability status and companion diagnostic claim...
